The abstract is read at the publisher; the summary is JClub's.
A new IASLC position paper proposes an updated pulmonary carcinoid/NET classification that adds Ki-67 and formally recognizes “carcinoid/NET G3” as a distinct rare subset.
- Why it matters: The 2021 WHO framework is being refined because molecular pathway insights and histopathologic proposals have expanded knowledge, creating a need for more precise tumor stratification and subtype-tailored therapies.
- What they did: The multidisciplinary panel reviewed the current pulmonary NEN landscape and proposed a classification update that shifts toward NET nomenclature while keeping “carcinoid” as the primary diagnostic term, adds Ki-67 as a criterion, and recognizes “carcinoid/NET G3.”
- The result: The proposed framework is intended to improve accurate categorization of pulmonary NENs and to guide treatment strategies, including for the rare “carcinoid/NET G3” subset with proliferative and molecular features distinct from high-grade neuroendocrine carcinomas.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.